摘要
骨质疏松症是一种常见的老年疾病,影响着全球数百万患者,现已成为阻滞健康老龄化进程的主要问题,研发新的治疗老年骨质疏松症的药物具有重要意义。内源性大麻素系统包含大麻素配体、内源性大麻素受体及合成和降解内源性大麻素所需的酶,在骨代谢中起着重要的作用。在动物模型和体外实验中使用基于内源性大麻素系统疗法的临床前研究表明内源性大麻素系统可以预防老年骨质疏松症,并显示出了其对老年骨质疏松症的治疗潜力。通过检索PubMed、ScienceDirect、中国知网及万方数据库收录的有关内源性大麻素系统和骨质疏松症相关研究的文章,分析老年骨质疏松症的发病机制(如钙、活性维生素D3缺乏或不足、性激素缺乏、细胞功能衰退及慢性疾病继发引起等),综述近年来内源性大麻素系统的各种成分、其通过调节成骨细胞和破骨细胞的功能影响骨稳态以及在骨质疏松症治疗中的应用进展,为老年骨质疏松症的临床治疗提供新的方向。
Osteoporosis is a common disease of old age that affects millions of people worldwide.Besides,it has been a chronic disease difficult to treat in the elderly,so it is of great significance to develop new drugs for the treatment of senile osteoporosis.The endocannabinoid system contains cannabinoid ligands,endocannabinoid receptors,and enzymes required for the synthesis and degradation of endocannabinoids,which play an important role in bone metabolism.Preclinical studies using endocannabinoid system-based therapies in animal models and in vitro have shown that endocannabinoid systems can prevent senile osteoporosis and highlight their therapeutic potential for senile osteoporosis.In this paper,PubMed,ScienceDirect,CNKY,and Wanfang databases were searched for articles related to the endocannabinoid system and osteoporosis.This paper analyzed the pathogenesis of senile osteoporosis(such as calcium,active vitamin D3 deficiency or insufficiency,sex hormone deficiency,cell function decline and secondary to chronic diseases,etc.),and reviewed the various components of the endocannabinoid system and their application in osteoporosis by regulating bone homeostasis in recent years,providing a new direction for the clinical treatment of senile osteoporosis.
作者
陈宇炯
钟家麒
彭兆祥
Chen Yujiong;Zhong Jiaqi;Peng Zhaoxiang(Department of Joint and Sports Medicine,the Affiliated Li-huili Hospital,Ningbo University,Ningbo 315040,China;Medical School of Ningbo University,Ningbo 315211,China)
出处
《中华骨科杂志》
CAS
CSCD
北大核心
2023年第3期197-204,共8页
Chinese Journal of Orthopaedics
基金
浙江省公益技术研究计划 (LGF21H060003)。
